Cardiovascular

Back to Pharmacology


Integrated Cardiopulmonary Pharmacology

Bruce J. Colbert, Barbara J. Mason

For courses in Cardiopulmonary Pharmacology. Targeted for Respiratory Therapy students, but also appropriate for Nursing programs. Marked by its readability and complete coverage, Integrated Cardiopulmonary Pharmacology is a truly introductory and interactive textbook, integrated with a unique self-study website that allows for continual updates of new drugs on the market as well as illuminating videos and animations. This text is indeed an integrated project, with an interdisciplinary perspective of both respiratory therapists and pharmacists; pharmacology integrated and linked to physiology/pathology to give total understanding and enhance relevant learning.

Drugs for the Heart, 5e

Lionel H. Opie MD DPhiL DSc FRCP, Bernard J. Gersh MB ChB DPhil FACC

An international cast of cardiologists now brings you DRUGS FOR THE HEART, 5th Edition. This New Edition is the definitive pocket-sized practitioner's guide to the complexities of cardiovascular drug therapy. Completely updated and with even more and better illustrations than ever, it presents the latest evidence-based information in the field.

Cardiovascular Pharmacotherapeutics (Current Medicine)

WIlliam Frishman, Edmund Sonnenblick, Domenic Sica

EVERYTHING PRACTICING PHYSICIANS AND PHARMACISTS NEED TO KNOW ABOUT DRUG THERAPY FOR HEART CONDITIONS

The updated Second Edition of this classic brings you fully up to speed on…


All the cardiovascular agents now available
Mechanisms of action of cardiovascular pharmacotherapeutics
Specific drug treatments
Drugs in development
Molecular biological advances
More

A compendium of valuable, updated pharmacotherapeutic information for managing patients with cardiovascular disease

Cardiovascular Pharmacotherapeutics has long been considered the primary reference for practicing physicians and pharmacists who need to know about drug therapy for heart conditions. This new Second Edition keeps pace with the latest drug discoveries and new therapeutic agents -- a task that challenges even specialists in the field.

Contributions from many of the leading investigators in cardiovascular pathophysiology and drug development

This timely second edition, primarily oriented toward specific drugs and drug classes, is co-edited and co-authored by three distinguished physician-scientists with important research accomplishments in cardiovascular pharmacology and pathophysiology. They provide you with:
An understanding of all presently available cardiovascular agents
The scientific basis behind every pharmacotherapy advance
Hands-on discussions of how to utilize specific drugs for treatment of various cardiovascular disorders and for the prevention of disease
Information about recently approved drugs that were only pharmacologic concepts in the previous edition
Detailed discussion of drugs in development and potential drug targets for innovative drug discovery – outgrowths of advances in knowledge of receptor and ion channel biology, cell growth, neurohumoral control, biochemistry and pathophysiology
More

Significant Features of the Second Edition


New section on New Drug Classes in Development keeps you abreast of this fast-evolving therapeutic area
Special Topics section provides additional information on drug-drug interactions, the use of cardiovascular drugs in children, the treatment of peripheral vascular disease, complementary medicine, and quality of life issues
Appendices provide you with practical, hands-on information on drug utilization in clinical practice

Cholesterol Control Without Diet!

William B. Parsons Jr.

2001 UPDATE: PAUL HARVEY STILL LIKES THIS BOOK!

On his 2/14/01 newscasts, Paul Harvey again referred to CHOLESTEROL CONTROL WITHOUT DIET! THE NIACIN SOLUTION. He cited a recent report at the American Heart Association annual meeting in which a combination of niacin and simvastatin (Zocor) reduced heart attacks and other coronary events by 70% in a 3-year study of persons who already had coronary disease. Then he asked his listeners not to say that Paul Harvey said they didn't have to diet and should take niacin, but he told them to have their doctors watch the New England Journal of Medicine later this year for the report.

He went on to say, "Meanwhile, YOU can read about the cholesterol matter in a book by Dr. William B. Parsons Jr." At this point he DID NOT give the book's title, sending listeners to their bookstores or to AMAZON.COM with just the author's name. He was right in saying that the book is readable by the general public and gives its readers a handle on the cholesterol situation they have not had before.

Here's the news release from which Mr. Harvey excerpted this item:

B-VITAMIN NIACIN IMPROVES RESULTS OF STATINS BY RAISING GOOD CHOLESTEROL. Combination Reduced Coronary Events by 'Phenomenal' 70%.

Niacin, a B-complex vitamin known as a cholesterol-reducing agent since 1955, greatly reduces heart attacks and strokes when used with "statin" drugs, according to two recent reports at meetings of heart specialists. Dr. Moti Kashyap (Long Beach, CA) and Dr. Greg Brown (Seattle) each studied niacin-statin combinations and found markedly better cholesterol results than with either drug alone. Both drugs lower bad cholesterol, which fell 45% in Kashyap's 800-patient VA study, but niacin also raises good cholesterol, which rose by 41%. Triglycerides, another hazardous blood fat, fell by 42%, also due to niacin. This study combined lovastatin (Mevacor) with niacin.

In Brown's study, which followed 160 patients with coronary disease for three years, niacin plus simvastatin (Zocor) reduced coronary events by 70%. Earlier studies had shown that niacin and statin drugs used singly reduced such events by 25% to 35%. Artery x-rays showed that progression of narrowing in coronary arteries was "virtually halted," Brown announced.

Dr. William Parsons (Scottsdale, AZ), a niacin proponent since he pioneered its use in US in the mid-1950's, called the reduction of events in Brown's study "truly phenomenal" because they were so much better than previous results with either drug alone. He pointed out that the statins reduce bad cholesterol, as niacin does, but niacin also raises good cholesterol, lowers triglycerides, and favorably changes several other cholesterol fractions, which no other form of treatment can match.

The National Cholesterol Education Program teaches that persons with previous coronary events require stricter control of cholesterol than others. Publicity about Vice-President Cheney's previous heart attack, bypass surgery, and his recent stent placement has brought this to the public's attention.

Full results of the Kashyap and Brown studies will be published later this year. Experts predict that doctors and patients will then be seeking information about niacin. In his book, CHOLESTEROL CONTROL WITHOUT DIET! THE NIACIN SOLUTION, Parsons tells how to use niacin successfully and manage its side effects, including flushing of the skin early in treatment. He assures that a skillful doctor can minimize or prevent flushing by using time-release niacin and starting each day with a plain aspirin tablet for the first few weeks.

It makes sense to start treatment with niacin because of its distinctive advantages, adding a statin only if niacin alone fails to control bad cholesterol adequately, Parsons advised. There is a major difference in expense, niacin costing $9 to $12 a month, compared to $50 to over $300 a month for the widely advertised statins. In recent years the US market for statins has been $7 to $8 billion annually.

Deadly Medicine: Why Tens of Thousands of Heart Patients Died in America's Worst Drug Disaster

Thomas J. Moore

Reveals the research reports that cited unusual patient deaths that occurred while testing the heart drug Tambocor and traces how the unsafe drug, and several like it, were released anyway, resulting in the deaths of thousands. 60,000 first printing.

Antiarrhythmic Drugs: A Practical Guide

Richard N. Fogoros MD

If you prescribe for patients with arrhythmias, you will want to keep this valuable paperback close at hand. The Second Edition of this valuable reference responds to changes in the available medications as well as in the way they are currently used.


The book reviews everything you need to understand and prescribe today’s antiarrhythmic drugs:



  • mechanisms of cardiac arrhythmias and how antiarrhythmic drugs alter those arrhythmias, including common adverse effects
  • which factors to consider in using these drugs for treatment of supraventricular tachyarrhythmias, ventricular arrhythmias, and arrhythmias in pregnancy
  • a detailed review of atrial fibrillation to help you make decisions for patient management in this complicated area

Dr. Fogoros considers all the most recent drugs, plus promising drugs under investigation, to give you a full picture of therapeutic options. With Antiarrhythmic Drugs: A Practical Guide, Second Edition, you will have dependable information on how each drug works and when each one is indicated so you can give your patients the best possible treatment.

Cardiac Drug Therapy

M. Gabriel Khan

This work, in its third edition, covers cardiac drug therapy, offering new material on ACE inhibitors and cardiac drugs in pregnancy and lactation, expanded material on thrombolytic agents, a quick reference section to individual drugs and more.

Cardiovascular Drug Therapy, 2e

Franz H. Messerli MD

This 2nd edition is the most up-to-date and complete catalog of cardiac drugs, and covers both individual drugs and therapeutic strategies. It is carefully revised to include every new drug in cardiac practice both in the United States and overseas. This reference contains information on drug interactions, combination therapy, and the use of cardiovascular agents in special populations such as the elderly, pregnant women, and physically active patients.

Laragh's Lessons in Renin System Pathophysiology for Treating Hypertension and Its Fatal Cardiovascular Consequences, 1e

John H. Laragh MD

Here's an essential reference for anyone needing an advanced understanding of the nature and treatment of hypertension. Dr. Laragh, a pioneering clinician and scientist, demonstrates the central role of an overactive renin system for causing most hypertension. In his new book, Dr. Laragh discusses his research and its relevance to caring for everything from asymptomatic patients to hypertensive emergencies. And, he provides visit-by-visit details of his new pathophysiologically and biochemically guided treatment. The result of his work is a specific approach that makes it possible to more effectively prevent, arrest, and treat hypertension and its consequences--including congestive heart failure, myocardial infarction, kidney failure and stroke.

Heparin Induced Thrombocytopenia (Fundamental and Clinical Cardiology)

Taking stock of advances in clinical recognition, laboratory testing, and pharmacologic therapy as well as basic aspects of pathogenesis, the Third Edition of Heparin-Induced Thrombocytopenia reinforces its standing as the leading guide to accurate diagnosis and effective management of this complex condition. Featuring added chapters on bivalirudin and pediatric heparin-induced thrombocytopenia (HIT), this reference also updates all 20 chapters of the previous edition to regard anew such topics as management of HIT using direct thrombin inhibitors and the special problems of renal failure and cardiac surgery in HIT patients.

Back to Pharmacology